Although useful to target the disease phenotype, the failure of JAK2 pharmacological inhibitors to eliminate LSC in BCR-ABL1-negative MPN suggests that targeting other elements associated with MPN pathogenesis is crucial. This evidence concerns the gene JAK2 and myeloproliferative disorder.